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Abstract
Coronary artery bypass grafting (CABG) today results in what may be regarded as acceptable levels
of blood loss with many institutions avoiding allogeneic red cell transfusion in over 60% of their
patients. The majority of cardiac surgeons employ cardiotomy suction to preserve autologous
blood during on-pump coronary artery bypass surgery; however the use of cardiotomy suction is
associated with a more pronounced systemic inflammatory response and a resulting coagulopathy
as well as exacerbating the microembolic load. This leads to a tendency to increased blood loss,
transfusion requirement and organ dysfunction. Conversely, the avoidance of cardiotomy suction
in coronary artery bypass surgery is not associated with an increased transfusion requirement.
There is therefore no indication for the routine use of cardiotomy suction in on-pump coronary
artery surgery.
Introduction
Coronary artery bypass grafting (CABG) today results in
what may be regarded as acceptable levels of blood loss
with many institutions avoiding allogeneic red cell trans-
fusion in over 60% of their patients [1,2]. The results of
on-pump coronary artery bypass surgery are excellent in
terms of early mortality [3]. However there remains signif-
icant associated morbidity, including bleeding and sec-
ondary organ dysfunction such as neurological and renal
impairment.
The cardiotomy suction apparatus was introduced in the
1960s as an extension of the intracardiac vent to allow
blood shed into the operative field to be returned to the
cardiopulmonary bypass (CPB) circuit. The aim was to
reduce blood loss and hence the need for allogeneic blood
transfusions with its known risk of mortality, other seque-
lae [4-6] and cost. Recent evidence however, suggests that
the return of shed blood by cardiotomy suction does not
reduce blood loss or blood transfusion requirement in
CABG [7,8]. On the other hand, it has been shown to
increase the burden of microembolisation and potentiates
the systemic inflammatory response.
Pericardial shed blood
Blood which has extravasated into the pericardial or pleu-
ral cavities and which is subsequently aspirated by cardi-
otomy suction differs markedly from intravascular blood
or blood within a closed CPB circuit. Surgical trauma from
opening the chest results in substantial tissue damage and
release of tissue factor [9,10]. Exposure of blood to tissue
factor results in rapid activation of the extrinsic pathway
of the coagulation system with release of thrombin and
fibrin. In addition, tissue plasminogen activator release
stimulates fibrinolysis. Analysis of pericardial shed blood
shows high concentrations of markers of clotting activa-
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tion [7]. Activation of the coagulation cascade inevitably
results in activation of the other inflammatory cascades.
High levels of inflammatory markers such as TNF-alpha,
IL-6, IL-8 and have been identified in pericardial shed
blood [8,13,14].
In addition to activation of the coagulation cascade, com-
plement system and fibrinolytic pathways, platelets are
activated when extravasation occurs into the pericardial
cavity. This results in aggregation, degranulation and con-
sumption of platelets, as well as the release of further
vasoactive substances [9,12].
The pericardial space also contains a mixture of debris
resulting from surgical trauma, most noticeably sternal
marrow fat and air microbubbles [15]. Thus, shed 'blood'
is far from pure and contains a substantial fraction of
potential embolic substances as well as activated platelets
and vaso-active mediators. It has been shown that these
additional constituents are likely to adversely affect flow
characteristics in the micro-circulation with shed blood
having grossly abnormal flow characteristics when passed
through a 5 micron filter [16].
Cardiotomy suction
Flow within the cardiotomy suction tubing differs signifi-
cantly from that in the CPB circuit. The concurrent suction
of air results in highly turbulent flow with high shear
stresses at the air-fluid interface. This causes cellular dam-
age as well as being a potent activator of all the humoral
cascades involved in the systemic inflammatory response.
Cardiotomy suction blood therefore contains an elevated
level of free haemoglobin [7,13,17] due to mechanical
haemolysis. High concentrations of free haemoglobin
cause platelet dysfunction and direct injury to the renal
tubular cells [18]. Similarly, platelet numbers are reduced
in cardiotomy suction blood through the rheological
trauma [19].
Re-transfusion of shed blood retrieved by 
cardiotomy suction
Retransfusing the vasoactive and activated inflammatory
mediators in shed blood into the patient's circulation
magnifies the systemic inflammatory response. In one
study where shed blood was retransfused, the plasma lev-
els of complement C3a, TNF-alpha, IL-6 were significantly
elevated compared to when there was no retransfusion
[8]. The clinical effect of this was demonstrated by a sig-
nificant reduction in systemic vascular resistance (SVR) at
the point of retransfusion [20]. This fall in SVR correlated
to the concentration of TNF-alpha returned to the circula-
tion.
Fat embolisation was known to be associated with cardi-
otomy suction as long ago as 1963 [21] when fat globules
were noted in the urine of patients where the blood over-
flowed into the pericardium at operation. The authors
associated this with the 'post-perfusion syndrome' and
advocated discarding this shed blood. Over three decades
later, Moody and colleagues demonstrated small capillary
and arteriolar dilatations (SCADs) in the brains and other
organs of patients who died following cardiopulmonary
bypass [22], and confirmed that they were in fact fat
emboli lodged within the vessels [23]. Cardiotomy suc-
tion blood is known to be saturated with fat released from
the subcutaneous tissue and sternal marrow on sternot-
omy [24,25].
Alternative strategies
There have been many attempts to reduce the problems
associated with cardiotomy suction by using filters. These
have been shown to reduce, but not eliminate the micro-
embolic load [26,27]. Greater reductions in embolic load
have been achieved with the use of serial filters [25] how-
ever filters do not have any beneficial impact upon the
other problems associated with cardiotomy suction,
namely derangement of coagulation and activation of
inflammatory cascades.
An alternative strategy which has been employed with
some success is to use controlled suction which reduces
the air-fluid interface and shear stress and thereby attenu-
ates haemolysis and the inflammatory response [19,28].
In an animal model, discarding the shed blood reduced
the lipid micro-embolic load more than ten fold com-
pared to when cardiotomy suction was used and the shed
blood reinfused [23]. A number of other studies compar-
ing the effects of cardiotomy suction plus retransfusion
versus discarding the cardiotomy suction blood in pri-
mary CABG have shown a significant reduction in the sys-
temic inflammatory response and haemolysis in the latter
group [8,14,29]. Moreover, this was not associated with
an increase in the transfusion requirement in the second
group but rather a trend towards increased mediastinal
bleeding [7,8,30], higher levels of circulating IL6, TNF and
C3a [8] and increased thrombin generation, PMN elastase
and beta thromboglobulin levels [14] when cardiotomy
suction was used, and the shed blood reinfused.
Intra-operative cell salvage
Red cell salvage has been in use in this country in cardiac
surgery in a few institutions since 1976. Its use however
became widespread following two Health Service Circu-
lars issued by the Chief Medical Officer recommending
cell salvage as a key component of the appropriate use of
blood [31,32]. Most cardiac units now employ intraoper-
ative cell salvage for complex cases and some use it rou-Page 2 of 5
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cardiopulmonary bypass.
Intraoperative autologous red cell salvage during cardiop-
ulmonary bypass is an attractive alternative to cardiotomy
suction. It allows the conservation of red blood cells
whilst reducing the retransfusion of fat micro-emboli,
activated coagulation and inflammatory markers. When
the blood is aspirated from the pericardium, heparin is
delivered at an appropriate rate to the tip of the suction
cannula to minimize activation of coagulation. The sal-
vaged blood is then stored in a reservoir containing addi-
tional heparinised saline prior to processing. During
processing the red cells are retained in the bowl whilst the
plasma, platelets, heparin, free haemoglobin, and inflam-
matory mediators are discarded with the wash solution.
This process may be discontinuous or continuous, and the
resulting red cells are finally resuspended at a haematocrit
of 50 – 70% in normal saline, and reinfused.
Fat microembolic load is decreased by the cell saver by as
much as 85% [25,26,33-35]. In an animal model of CPB;
the processing of shed blood by a cell saver resulted in a
significant reduction in the formation of SCADs [25].
Indeed there is some evidence that the continuous
autotransfusion devices may now be capable of removing
100% of fat from cell salvage blood [33].
The process of cell salvage results in the activation of white
blood cells leading to the release of inflammatory media-
tors (IL-6, C5a, C3a, terminal complement complexes).
However unlike cardiotomy suction blood, the centrifuga-
tion and washing processes reduce the concentration of
white blood cells by 30 – 80% and inflammatory media-
tors by 90 – 95% as they are discarded in the wash solu-
tion [36].
Cell salvage is not however entirely without problems; the
issue of air-fluid interfaces remains, although the avoid-
ance of "skimming" and the presence of heparin at the tip
of the suction apparatus reduces the activation of the clot-
ting and inflammatory cascades. It is also easy to under-
stand that if very large volumes of blood are processed
through a cell saver it will deplete that volume of blood of
platelets and clotting factors, careful monitoring and
replacement of these may be necessary.
A small number of studies have shown no adverse effect
on mediastinal drainage or transfusion requirements
when a cell saver is used to replace cardiotomy suction in
coronary surgery [17,30]. A small randomised clinical trial
(20 vs 20), demonstrated that reinfusion of cell saved
blood did not increase mediastinal blood loss or blood
product usage [34]. These published studies were sup-
ported by the results of an audit in our own institution (of
first time CABG; 2004–05) in which there was a trend for
blood loss or product usage to be higher in those patients
managed with cardiotomy suction rather than cell salvage.
Contemporary clinical studies
It is conceivable that many of the reported benefits attrib-
uted to mini-extracorporeal circulation (MECC) systems
and off-pump CABG (decreased bleeding, decreased
inflammatory response and reduced micro-emboli) may
at least in part be attributable to the avoidance of cardiot-
omy suction. Recent developments in CPB designed to
minimise its adverse effects resulted in MECC systems
comprising of a short, reservoir-free, heparinised circuit
with a centrifugal pump and membrane oxygenator [37].
The closed-circuit design without cardiotomy suction and
vents eliminates any air-fluid interface, and pericardial
shed blood is not reinfused. Several studies comparing
MECC circuits to crude cardiopulmonary bypass circuits
have found an attenuated systemic inflammatory
response [38], reduced microembolisation [39] and
reduced the need for red cell transfusion [40] associated
with the former. It is likely that the elimination of cardiot-
omy suction contributed significantly to the improved
outcome of these patients, and further studies are required
to compare MECC directly to CPB without cardiotomy
suction.
The elimination of CPB and cardiotomy suction alto-
gether in off-pump coronary artery bypass (OPCAB) is
also associated with a reduced systemic inflammatory
response [41,42], lower transfusion rate [43] and fewer
microemboli [44]. Whilst there is some evidence that the
organ protective effects of MECC approximates that of
OPCAB [45], a direct comparison between OPCAB and
CPB without cardiotomy suction is required to ascertain
whether the elimination of cardiotomy suction is enough
to explain the difference.
Summary
We know that conventional CPB induces a systemic
inflammatory response and results in microembolism to
the brain and other organs. Salvage of shed blood by car-
diotomy suction exacerbates the inflammatory response
and increases the load of lipid emboli to the brain (and by
implication, all other capillary beds). Discarding shed
mediastinal blood will attenuate these adverse effects but
at the cost of losing red cells mass. Cell salvage is an attrac-
tive alternative although current evidence suggests that the
complications associated with reinfusing shed blood may
be attenuated rather than eliminated.
We hope that we have demonstrated that there is good
evidence that CABG can be safely performed without the
use of cardiotomy suction, with red cell salvage, and with-
out an increase in blood loss or blood usage. Despite thisPage 3 of 5
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nately used during coronary artery bypass surgery, and
although in the presence of rapid significant blood loss its
use is justified, its continuous application in the operative
field is not.
Conclusion
There is robust, published, clinical evidence that salvage
of shed blood by cardiotomy suction and its reinfusion is
deleterious to patients undergoing coronary artery bypass
surgery and we suggest that there is no indication for its
routine use in this group. We conclude that cell salvage
represents an acceptable alternative to cardiotomy suction
by attenuating the deleterious effects of the reinfusion of
cardiotomy suction blood whilst preserving the red cell
mass.
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